Q2
ACET — Q2 2026 Financial Report Analysis
Adicet Bio's Q2 2026 net loss narrowed 32% to $21.4 million, partly because its lupus trial stopped enrolling new patients, leaving $118.2 million in cash (guided to last into 2H 2027) to carry prula-cel toward a pivotal lupus nephritis study.